Safety and efficacy of hybrid closed‐loop insulin pump therapy in adolescents and adults with type 1 diabetes in China
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70227 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Jing Shen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, The Eighth Medical Center of PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Insulin Infusion Systems, Hypoglycemic Agents, Insulin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
To evaluate the effectiveness and safety of a hybrid closed‐loop (HCL) insulin infusion system in treating adult and adolescent patients with type 1 diabetes (T1D). Materials and Methods A total of 126 participants (22 adolescents and 104 adults) underwent a 2‐week initial treatment phase followed by a 2‐week run‐in phase with the Equil® S HCL insulin pump system MTM‐Z in Manual Mode with calibration‐free continuous glucose monitoring (CGM) System G7, followed by a 12‐week study phase with HCL Auto Mode enabled. The primary outcome was the overall mean change in CGM time in range (TIR; 70–180 mg/dL). Safety endpoints included rates of severe hypoglycaemia, hyperglycaemia and diabetic ketoacidosis (DKA).
Results
Compared with the baseline run‐in, Auto Mode increased TIR from 69.11% to 76.72% ( p < 0.001) and reduced time below range (70% increased from 56.03% to 77.59%. The standard deviation (SD: −5.90 mg/dL) and coefficient of variation (CV: −2.49%) reduced significantly. The greatest change in TIR (mean 20.55%), mean SG (estimated treatment difference [ETD]: −30.13, 95% confidence interval [CI]: −41.84, −18.41; p = 0.001) and SD of SG (ETD: −14.21, 95% CI: −21.17, −6.71; p = 0.004) was observed in participants with a baseline glycosylated haemoglobin A1c (HbA1c) value of >8.0%. The percentage of achieving combined recommendations for time at SG ranges increased from 25.86% to 56.90%. No severe hypoglycaemia, DKA or adverse events were observed.
Conclusions
HCL therapy is safe in Chinese adolescent and adult patients with T1D. The 12‐week application of the Equil® S HCL insulin pump system MTM‐Z with Auto Mode increased TIR and reduced HbA1c, hyperglycaemia and hypoglycaemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, The Eighth Medical Center of PLA General Hospital, Beijing, China.
- Department of Endocrinology, Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China.
- Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
- Department of Endocrinology, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- Department of Endocrinology, Beijing Pinggu Hospital, Beijing, China.
- Department of Endocrinology, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China.
ORCID-Profile: Xia Li, Xiaohong Wu, Yang Liu, Yiming Mu
Zitieren
APA
Shen, J., Zeng, T., Li, X., Zheng, C., Li, Y., Wu, X., Yao, H., Chen, L., Liu, Y., Zhu, W., Fu, J., Zhao, W., & Mu, Y. (2026). Safety and efficacy of hybrid closed‐loop insulin pump therapy in adolescents and adults with type 1 diabetes in China. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70227
Vancouver
Shen J, Zeng T, Li X, Zheng C, Li Y, Wu X, et al. Safety and efficacy of hybrid closed‐loop insulin pump therapy in adolescents and adults with type 1 diabetes in China. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70227
BibTeX
@article{Shen2026,
author = {Shen, Jing and Zeng, Tianshu and Li, Xia and Zheng, Chao and Li, Yufeng and Wu, Xiaohong and Yao, Hui and Chen, Linqi and Liu, Yang and Zhu, Weiwei and Fu, Junfen and Zhao, Weigang and Mu, Yiming},
title = {Safety and efficacy of hybrid closed‐loop insulin pump therapy in adolescents and adults with type 1 diabetes in China},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70227}
}
EUVIMED